semaglutide who qualifies For the first time, Medicare will cover GLP-1s for obesity-related weight loss, without any other medical conditions. Starting Wednesday, eligible Medicare beneficiaries can receive GLP-1s for obesity for $50 per month by Eligible Medicare Part D Members

Semaglutide slows gastric emptying and acts on brain appetite centers, which can cause nausea, especially with high-fat or large-portion breakfasts

Kumar, A., Wissbrock, A., Goradia, N., Bellstedt, P., Ramachandran, R., Imhof, D

Presented for research literature review only O'Leary K (2023)

This proactive approach prevents deficiencies that could undermine the clinical benefits and long-term sustainability of your GLP-1 treatment

This product is supplied as a 10 mg lyophilized sterile powder in vials, which must be reconstituted with bacteriostatic water before administration

This dual action helps regulate blood glucose levels without causing hypoglycemia when glucose levels are normal